SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
49878<As to VKTX, I had an order in to sell some at $5.38 price point, and that hiMiljenko Zuanic-4/15/2018
49877My take on the price action. ( I hold both MDGL and VKTX. ) MDGL traders got iBiotech Jim-4/14/2018
49876Pretty weird reaction in the stock prices of MDGL and VKTX. No clue why that reaBiomaven-4/14/2018
49875Direct comparison of the 36w MRI-PDFF (and biomarkers) and Liver biopsy will broMiljenko Zuanic-4/13/2018
49874Right you are, DD. Here is what GS has to say this morning regarding the MDGL tBiotech Jim-4/13/2018
49873Nitpick: The Roth analyst cites a “potential hypothesis” to explain observed BP-DewDiligence_on_SI-4/13/2018
49872<Hey Jim, so they won't have clear data about fibrosis until the 36 week Biotech Jim-4/13/2018
49871Results from liver enzyme, inflammatory and fibrosis biomarker data, including aatticus4paws-4/13/2018
49870Cowan summary on the MDGL presentation at EASL, took place some 5 hrs ago in ParBiotech Jim-4/13/2018
49869$3.50 per day (in lower income countries) HCV treatment: theguardian.comnigel bates34/12/2018
49868>>Equal weight at reset dates. Nktr was one of highest weights pre move. Biomaven-4/11/2018
49867Equal weight at reset dates. Nktr was one of highest weights pre move. JonRobohogs-4/10/2018
49866Thanks. Aren't they weighted by capitalization? Only five companies exceedA.J. Mullen-4/10/2018
49865I knew it had AVXS when I saw the gap and NKTR I knew. ACAD (oops) and AGIO I haRobohogs-4/10/2018
49864^BTK is up over 6% as I type. The biotech I follow are up nicely, but none closA.J. Mullen-4/9/2018
49863You might be able to rerun the experiment needle free soon: nature.comnigel bates-4/9/2018
49862ACAD down on CNN article cnn.comJamesK14/9/2018
49861Novartis just took a big punt (in the betting, rather than football sense) on thnigel bates-4/9/2018
49860Sepsis therapy in trial by Contrafect. Results out by December clinicaltrials.gteevee-4/8/2018
49859This is an interesting antibiotic approach which might help avoid sepsis, as it nigel bates-4/8/2018
49858So their main trial failed, but they are trying to do a subset analysis. ThatBiomaven14/8/2018
49857It's key to think about prevalence as well as incidence. If the drug is realBiomaven24/8/2018
49856Potentially exciting but wondering the size of the market. The ALK drugs combineJamesK14/8/2018
49855Ugghh. Reminded me of 3-4 big portfolio failures lol. Was it CNTO or CHIR? ForgRobohogs-4/7/2018
49854Obviously, they do not!Miljenko Zuanic-4/7/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News